In order for us to continue to organise conferences and events to benefit people with narcolepsy, it is vital that we are able to show to potential donors that our events are of value to our community.
The following items can be useful to supply with any benefit applications relating to narcolepsy. It will be helpful to you if you can gather as many of them as possible to include with your application.
Flamel (Part of the Avadel Pharmaceuticals), are looking for subjects to participate in their clinical trial evaluating their once nightly sodium oxybate for the treatment of EDS and cataplexy in narcolepsy.
FT218 is dosed once at bedtime unlike the currently marketed formulation of sodium oxybate (Xyrem®) which needs to be taken twice nightly, once at bedtime and then again 2.5 – 4 hours later.
Patients with a diagnosis of narcolepsy who meet the study criteria may be eligible to participate in our clinical trial.
When a new medicine is first developed and approved for use, it is usually only available from one manufacturer. Normally, that is the company that invented it and that obtained the first authorisation for its use, after steering the drug through the complex and expensive process of clinical trials.